Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid

Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid

Due to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and paxlovid. Our aim was to establish and validate...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng-Fei Tang, Su-Su Bao, Wei-Fei Xie, Zhong-Xiang Xiao, Xue-Meng Wu, Hong-Lei Ge
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
firmonertinib
drug interactions
UHPLC-MS/MS
pharmacokinetics
paxlovid
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1570206/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items